Compare RDNW & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDNW | ALXO |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United States |
| Employees | 1906 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 250.8M | 205.9M |
| IPO Year | N/A | 2020 |
| Metric | RDNW | ALXO |
|---|---|---|
| Price | $6.43 | $1.95 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $6.50 | $3.50 |
| AVG Volume (30 Days) | 67.5K | ★ 858.8K |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.01 | N/A |
| Revenue Next Year | $6.53 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.98 | $0.51 |
| 52 Week High | $8.55 | $2.66 |
| Indicator | RDNW | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 55.58 | 47.99 |
| Support Level | $6.28 | $1.42 |
| Resistance Level | $7.22 | $2.31 |
| Average True Range (ATR) | 0.33 | 0.15 |
| MACD | 0.12 | -0.02 |
| Stochastic Oscillator | 82.10 | 18.18 |
RideNow Group Inc operates solely as a powersports dealership group. Its offerings include new and pre-owned vehicles such as motorcycles, all-terrain vehicles (ATVs), side-by-side vehicles (SXS), and personal watercraft (PWC). It also sells parts, apparel, and accessories, and provides financing, insurance, and aftermarket products, along with repair and maintenance services. The majority of the company's revenue is derived from powersports vehicle sales, and the rest from parts, service and accessories/merchandise, and finance and insurance products.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.